
Chemical Protein Synthesis – my Journey from SPPS to Chemical Ligation
Stephen Kent
Professor, University of Chicago
The total synthesis of proteins was one of the ‘Grand Challenges’ of 20th century chemistry. Despite decades of development by skilled organic chemists throughout the world, conventional synthetic methods and stepwise SPPS were able to make only the smallest proteins. In 1992 we introduced the chemical ligation principle – the condensation of unprotected peptide segments by chemoselective reaction enabled by formation of an unnatural bond at the ligation site. [1] In 1994 we introduced the native chemical ligation reaction, thiol ester-mediated condensation of unprotected peptide segments to give a native peptide bond at the ligation site. [2] In combination with peptide synthesis by state- of-the-art SPPS, modern chemical ligation methods enable total chemical synthesis of proteins including enzymes. [3,4] Synthetic protein products are characterized by high resolution methods including LCMS, multidimensional NMR, and X-ray crystallography. Chemical protein synthesis gives precise, atom-
by-atom control over the covalent structure of a protein molecule. Case studies of the application of chemical protein synthesis to the enzyme HIV-1 protease will be described. Efficient total synthesis of human insulin will also be presented, together with site-specific 13 C= 18 O isotope labelling of individual peptide bonds in the insulin molecule for time-resolved FTIR spectroscopy.
References
1. Constructing proteins by dovetailing unprotected synthetic peptides: backbone engineered
HIV protease. M. Schnölzer, S. Kent Science, 256, 221-225 (1992).
2. Synthesis of proteins by native chemical ligation. Philip E. Dawson, Tom W. Muir, Ian Clark-
Lewis, Stephen B.H. Kent, Science, 266, 776-779 (1994).
3. Chemical protein synthesis: inventing synthetic methods to decipher how proteins work.
Stephen B.H. Kent, Bio Org Med Chem., 25, 4926-4937 (2017).
4. Novel protein science enabled by total chemical synthesis. Kent SBH. Protein Science 2019;
28:313–328
Stephen B. H. Kent received his first two university degrees in his native New Zealand and his Ph.D. (Organic Chemistry) from University of California, Berkeley. Following postdoctoral work with Bruce Merrifield, Professor Kent held faculty appointments at the Rockefeller University, the California Institute of Technology, and The Scripps Research Institute. He was Founder of Gryphon Sciences and served as its Chief Scientific Officer from 1997-2000. In 2001, he joined the faculty of the University of Chicago, where since June 2021 he is Professor Emeritus of Chemistry, Biochemistry and Molecular Biology.
Over the past several decades, Stephen Kent has profoundly shaped the field of peptide and protein chemistry. His many and diverse contributions have altered the way scientists tackle the study of these macromolecules. He pioneered the total chemical synthesis of protein molecules and showed it to be a practical and versatile method for the production of large quantities of high purity material for detailed mechanistic and structural investigations. In particular, the Kent chemical ligation concept together with the native chemical ligation reaction made proteins and enzymes accessible to direct chemical investigation via convergent, chemoselective assembly of unprotected synthetic peptide segments.
Since its introduction in 1994, native chemical ligation has become robust, reliable, and widely used. Efficient total chemical synthesis of a wide range of protein molecules, including the enzymes HIV-1 protease and human lysozyme, the protein hormone human insulin, glycoprotein mimetics of erythropoietin, together with numerous mirror image protein molecules for his pioneering studies of racemic protein crystallography, highlight the practical utility of such approaches. As these examples attest, Stephen Kent has had a gift, throughout his career, for developing new chemistries and for utilizing them to reveal the molecular basis of protein function.
His exceptional achievements in scientific research have previously been recognized by the receipt of major distinctions, including the ACS Hirschmann Award in Peptide Chemistry (1994), the Protein Society E.T. Kaiser Award (2002), the Vincent du Vigneaud (2004) and R. Bruce Merrifield (2009) Awards of the American Peptide Society, the European Peptide Society Rudinger Medal (2010), the Japanese Peptide Society Akabori Medal (2010), the ACS Alfred Bader Award in Bioorganic Chemistry (2011), and more.
The Boulder Peptide Foundation was established to further the science and knowledge of peptide technology to develop novel therapeutics, biomaterials, medical diagnostics and other beneficial uses for mankind. As part of this goal we run several programs to support career advancement, seminars and educational events. Join us on our mission to expand the applications of peptide science.
The purpose of the Boulder Peptide Symposium is to encourage sharing of information related to peptide therapeutic development with an emphasis on the technical, scientific and regulatory aspects of the pharmaceutical development. Presentations that demonstrate original thinking or share experiences from case studies in product development shall receive priority over others.
The Boulder Peptide Symposium offers multiple opportunities for participants to present.
The session topics for Scientific Program are Peptides in the Clinic, Drug Delivery, Chemistry of Complex Peptides, Spotlight on Discovery, and Peptide Showcase. Abstracts may be submitted via the Apply to Present page on the website. Submissions will be reviewed by the Scientific Advisory Board on a monthly basis and the speaker will be notified of a decision.
Presentation length: Format is 25-30 minutes slide presentation with 5-10 minutes for Q&A, with the exception of Peptide Showcase talks which are 10 minute slide presentations with 5 minutes for Q&A. Please confirm with your session chair to confirm the exact presentation length.
Invited Speakers: Speakers are requested to supply their presentation details 30 days after receiving an invitation to present.
Program Book Deadline: Final abstract and title must be provided no later than September 1st. No changes to the program are possible after this date.
Presentation Format: Oral presenters please provide your presentation slides to the A/V table on the day of your presentation.
Lodging: All speakers are requested to reserve their own room. Discount rates at the conference hotel are available until August 16th.
Registration: All speakers, excluding sponsored presentation speakers, receive a complimentary registration upon approval of the abstract.
The Peptide Showcase is an opportunity for an individual or company to “showcase” new ideas, technology and pipeline assets. Priority shall be given to presentations from biotech and startup companies. Service providers and vendors are not eligible. Speakers in the session receive a complimentary event registration.
Posters can be presented on any topic relevant to peptides including original research, innovative products and technologies.
Eligibility- Any attendee (from academia, industry, biotech or vendor/sponsor) can present a poster. The presentation must contain original scientific thinking. To submit a poster go to the Submit a Poster link from the meeting menu. All submissions are reviewed on a rolling basis and will be notified of approval. September 1st is the last day to submit a poster abstract. Approved posters are published on the BPF website.
A 30 ” x 40″ board shall be provided with thumb tacks. Board will be on an easel and can be rotated for either landscape or portrait formats. Once you apply for a poster, you will get email confirmation that your poster was accepted. The poster session and number assignments will be emailed one week before the Symposium.
Poster boards shall be available for display from 8am to 8pm the day of your assigned poster session. See the program agenda for the poster session schedule.
Every presentation at the Boulder Peptide Symposium is automatically recorded. Speakers are required to give consent for sharing of the presentation video with the peptide community.